Ποια είναι η τιμή για Marizyme, Inc. (MRZM)

Η τιμή για Marizyme, Inc. (MRZM) είναι $0.0003

Ποια είναι η κεφαλαιοποίηση αγοράς για Marizyme, Inc. (MRZM)

Η κεφαλαιοποίηση αγοράς για Marizyme, Inc. (MRZM) είναι $39.54K

Marizyme, Inc. (MRZM) Τιμή και Κεφαλαιοποίηση Αγοράς

Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.

Η τιμή για MRZM	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$41,335.45 $39.54K	NVDA	$5.448T	+13,778,482,548.79%
$33,887.38 $39.54K	AAPL	$4.466T	+11,295,793,886.94%
$31,567.37 $39.54K	GOOG	$4.160T	+10,522,457,812.91%
$28,121.89 $39.54K	MSFT	$3.706T	+9,373,963,310.20%
$21,931.56 $39.54K	AMZN	$2.890T	+7,310,518,331.16%

Η τιμή για MRZM

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$41,335.45 $39.54K